AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32437857 — intervention group
Group type: COMPARATOR
Intervention: Two-step impression in custom trays with border molding (impression compound) followed by polyether impression
Number of subjects: 52
Study 34936992 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention
Number of subjects: 104
Study 32993773 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 224
Study 32993773 — intervention group
Group type: COMPARATOR
Intervention: Warfarin plus nadroparin
Number of subjects: 224
Study 35566250 — intervention group
Group type: EXPERIMENTAL
Intervention: A. tricolor accessions
Number of subjects: 8
Study 35566250 — intervention group
Group type: EXPERIMENTAL
Intervention: A. lividus accessions
Number of subjects: 8
Study 35566250 — intervention group
Group type: EXPERIMENTAL
Intervention: A. tricolor and A. lividus accessions
Number of subjects: 8
Study 35566250 — intervention group
Group type: EXPERIMENTAL
Intervention: Accession AT2
Number of subjects: 8
Study 35566250 — intervention group
Group type: EXPERIMENTAL
Intervention: Accession AT5
Number of subjects: 8
Study 35566250 — intervention group
Group type: EXPERIMENTAL
Intervention: Accession AT12
Number of subjects: 8
Study 35566250 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation study
Number of subjects: 8
Study 34765229 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume injection with corticosteroid
Number of subjects: 192
Study 34765229 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume injection without corticosteroid
Number of subjects: 192
Study 34765229 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 192
Study 35605593 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion plus acupuncture
Number of subjects: 60
Study 35605593 — intervention group
Group type: COMPARATOR
Intervention: Standard stroke treatment protocol including acupuncture
Number of subjects: 60
Study 33901276 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically-determined higher TSH in low BMI group
Number of subjects: 408895
Study 33901276 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically-determined higher TSH
Number of subjects: 408895
Study 33901276 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically-determined fT4 levels
Number of subjects: 408895
Study 33122787 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior plate
Number of subjects: 15
Study 33122787 — intervention group
Group type: COMPARATOR
Intervention: Anteroposterior (AP) lag screws
Number of subjects: 15
Study 33122787 — intervention group
Group type: COMPARATOR
Intervention: Posteroanterior (PA) lag screws
Number of subjects: 15
Study 34763236 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 in. chest compression depth
Number of subjects: 40
Study 34763236 — intervention group
Group type: COMPARATOR
Intervention: 1/3 the anterior‐posterior diameter (APd) chest compression depth
Number of subjects: 40
Study 34106667 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding before the operation
Number of subjects: 0
Study 34106667 — intervention group
Group type: COMPARATOR
Intervention: No special treatment (Control group)
Number of subjects: 0
Study 32427280 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-based contrast
Number of subjects: 140
Study 32427280 — intervention group
Group type: COMPARATOR
Intervention: Water-based contrast
Number of subjects: 140
Study 35422134 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening Group (SG) - biennial prostate specific antigen testing
Number of subjects: 20000
Study 35422134 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 20000
Study 34452734 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE with bleomycin
Number of subjects: 170
Study 34452734 — intervention group
Group type: COMPARATOR
Intervention: TACE with doxorubicin
Number of subjects: 170
Study 35902830 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus strain GG (LGG) probiotic supplementation
Number of subjects: 0
Study 33507839 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 29
Study 33507839 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 29
Study 33348678 — intervention group
Group type: EXPERIMENTAL
Intervention: FTO rs9939609 A‐allele (AA)
Number of subjects: 24
Study 33348678 — intervention group
Group type: COMPARATOR
Intervention: FTO rs9939609 T‐allele (TT)
Number of subjects: 24
Study 35326326 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorogenic acids (CGA) 270 mg
Number of subjects: 26
Study 35326326 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 26
Study 33669905 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cardiorespiratory fitness (CRF)
Number of subjects: 832
Study 33669905 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher physical activity (PA)
Number of subjects: 832
Study 33669905 — intervention group
Group type: EXPERIMENTAL
Intervention: CRF/PA quartiles
Number of subjects: 832
Study 36501148 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ)
Number of subjects: 11
Study 36501148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 32701188 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg
Number of subjects: 306
Study 32701188 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 100 mg
Number of subjects: 306
Study 32701188 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg
Number of subjects: 306
Study 36342251 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling followed by 35% glycolic acid (GA) peel
Number of subjects: 40
Study 36342251 — intervention group
Group type: COMPARATOR
Intervention: Microneedling followed by 15% trichloroacetic acid (TCA) peel
Number of subjects: 40
Study 33201029 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat-based PISQ-12 questionnaire
Number of subjects: 120
Study 33201029 — intervention group
Group type: COMPARATOR
Intervention: Paper version of PISQ-12 questionnaire
Number of subjects: 120
Study 33201029 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat questionnaire
Number of subjects: 120
Study 35583992 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC with cisplatin
Number of subjects: 245
Study 35640081 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive programs (intervention group)
Number of subjects: 36
Study 35640081 — intervention group
Group type: COMPARATOR
Intervention: Routine oral health education (control group)
Number of subjects: 36
Study 32251254 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS + TE
Number of subjects: 90
Study 32251254 — intervention group
Group type: COMPARATOR
Intervention: TE alone
Number of subjects: 90
Study 34750670 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra wound vancomycin (1-2 g)
Number of subjects: 375
Study 34750670 — intervention group
Group type: COMPARATOR
Intervention: No drug (control group)
Number of subjects: 375
Study 34538239 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily clinical warning signs (CWS) assessment
Number of subjects: 843
Study 34538239 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily risk scores using 7 CWS and MUAC<10.5cm
Number of subjects: 843
Study 34538239 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting top 5 CWS
Number of subjects: 843
Study 34538239 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of 1 or 2 CWS on any day during hospitalization
Number of subjects: 843
Study 32701242 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine combined with protective ventilation strategy (DF group; n=20)
Number of subjects: 40
Study 32701242 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary protective ventilation strategy (F group)
Number of subjects: 40
Study 35359485 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol box (AB) with PPE
Number of subjects: 40
Study 35359485 — intervention group
Group type: COMPARATOR
Intervention: PPE alone (Control)
Number of subjects: 40
Study 34016139 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional printing individual guide template-assisted percutaneous vertebroplasty (group A)
Number of subjects: 36
Study 34016139 — intervention group
Group type: COMPARATOR
Intervention: Conventional PVP guided by C-arm fluoroscopy (group B)
Number of subjects: 36
Study 34689382 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed/cisplatin (Pem/Cis)
Number of subjects: 389
Study 34689382 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine/cisplatin (Vnr/Cis)
Number of subjects: 389
Study 35841050 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels
Number of subjects: 60
Study 35841050 — intervention group
Group type: COMPARATOR
Intervention: Control group (sex and age matched)
Number of subjects: 60
Study 34548307 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 0
Study 34548307 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab emtansine
Number of subjects: 0
Study 35587794 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving gratings combined with standard occlusion
Number of subjects: 37
Study 35587794 — intervention group
Group type: COMPARATOR
Intervention: Stationary gratings combined with standard occlusion
Number of subjects: 37
Study 34811410 — intervention group
Group type: EXPERIMENTAL
Intervention: Process-simulation with elements of relaxation
Number of subjects: 150
Study 34811410 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome-simulation with elements of relaxation
Number of subjects: 150
Study 34811410 — intervention group
Group type: COMPARATOR
Intervention: Control group with elements of relaxation only
Number of subjects: 150
Study 35562821 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV risk reduction intervention
Number of subjects: 20
Study 33185043 — intervention group
Group type: EXPERIMENTAL
Intervention: New technique for laparoscopic para-aortic lymphadenectomy (PAL)
Number of subjects: 37
Study 33185043 — intervention group
Group type: COMPARATOR
Intervention: Control method for laparoscopic para-aortic lymphadenectomy (PAL)
Number of subjects: 37
Study 32760749 — intervention group
Group type: EXPERIMENTAL
Intervention: Beating the Blues US (BtB) - 8-session internet cognitive-behavioral therapy for depression
Number of subjects: 54
Study 32760749 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 54
Study 35270810 — intervention group
Group type: EXPERIMENTAL
Intervention: New model of providing preventive care (healthy choices consultation, embedding risk factors into care plans, continuation of preventive care by mental health clinicians)
Number of subjects: 12
Study 35270810 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 12
Study 33085516 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified lycopene (LYC) supplementation at 20 mg/kg diet for 12 weeks
Number of subjects: 150
Study 33085516 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato powder (TP) supplementation at an equal amount of lycopene for 12 weeks
Number of subjects: 150
Study 33085516 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (control)
Number of subjects: 150
Study 33201059 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluorometholone (FML)
Number of subjects: 72
Study 33201059 — intervention group
Group type: COMPARATOR
Intervention: Topical cyclosporine A (CSA) 0.5% eye drops
Number of subjects: 72
Study 32044755 — intervention group
Group type: COMPARATOR
Intervention: Facebook posts
Number of subjects: 211
Study 32044755 — intervention group
Group type: COMPARATOR
Intervention: Facebook posts plus text messages
Number of subjects: 211
Study 32044755 — intervention group
Group type: COMPARATOR
Intervention: Control group (electronic leaflet)
Number of subjects: 211
Study 33293079 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant radiotherapy with chemotherapy (cRT)
Number of subjects: 117
Study 33293079 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy without concomitant chemotherapy (RT)
Number of subjects: 117
Study 33023501 — intervention group
Group type: EXPERIMENTAL
Intervention: Community outreach
Number of subjects: 105
Study 33023501 — intervention group
Group type: COMPARATOR
Intervention: GP letters
Number of subjects: 105
Study 36177347 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil (TD) 245 mg
Number of subjects: 189
Study 36177347 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate (TDF) 300 mg
Number of subjects: 189
Study 33676866 — intervention group
Group type: EXPERIMENTAL
Intervention: Latissimus dorsi (LD) flap
Number of subjects: 50
Study 33676866 — intervention group
Group type: COMPARATOR
Intervention: Thoracodorsal artery perforator (TAP) flap
Number of subjects: 50
Study 32171731 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapler device
Number of subjects: 70
Study 32171731 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 70
Study 32171731 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 70
Study 35643710 — intervention group
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Number of subjects: 0
Study 35643710 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 0
Study 32294276 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass index
Number of subjects: 367703
Study 32294276 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free mass index
Number of subjects: 367703
Study 35641971 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component workplace interventions targeting sedentary behavior or increasing physical activity
Number of subjects: 263
Study 35641971 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 263
Study 33200722 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT for leprosy (600 mg rifampicin, 300 mg clofazimine, 100 mg dapsone monthly; 50 mg clofazimine and 100 mg dapsone daily)
Number of subjects: 103
Study 33200722 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT for leprosy plus itraconazole (100 mg twice daily)
Number of subjects: 103
Study 33200722 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who did not adhere to therapeutic regimens)
Number of subjects: 103
Study 32185477 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training in hypoxia (IHT)
Number of subjects: 82
Study 32185477 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated sprint training in hypoxia (RSH)
Number of subjects: 82
Study 32185477 — intervention group
Group type: COMPARATOR
Intervention: Interval training in normoxia (INT)
Number of subjects: 82
Study 32185477 — intervention group
Group type: COMPARATOR
Intervention: Repeated sprint training in normoxia (RSN)
Number of subjects: 82
Study 33596993 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg p.o. twice/day)
Number of subjects: 100
Study 33596993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermentable fibers (35 g/day)
Number of subjects: 100
Study 33596993 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metformin plus fiber
Number of subjects: 100
Study 33163157 — intervention group
Group type: EXPERIMENTAL
Intervention: Routinely collected health data (RCHD)
Number of subjects: 216
Study 34955237 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy (TLH)
Number of subjects: 279
Study 34955237 — intervention group
Group type: COMPARATOR
Intervention: Total Abdominal Hysterectomy (TAH)
Number of subjects: 279
Study 33603000 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Dietary Approaches to Stop Hypertension (DASH) diet
Number of subjects: 100
Study 33603000 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH and exercise group
Number of subjects: 100
Study 33603000 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 32182380 — intervention group
Group type: EXPERIMENTAL
Intervention: PR/RP+EMD
Number of subjects: 50
Study 32182380 — intervention group
Group type: COMPARATOR
Intervention: PR/RP+saline
Number of subjects: 50
Study 36155536 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk stabilization exercise program using weight loads
Number of subjects: 30
Study 36155536 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk stabilization exercise program
Number of subjects: 30
Study 36155536 — intervention group
Group type: COMPARATOR
Intervention: General physiotherapy
Number of subjects: 30
Study 34674404 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled anticonvulsants and benzodiazepines as needed
Number of subjects: 75
Study 34674404 — intervention group
Group type: COMPARATOR
Intervention: Usual care (benzodiazepines as needed)
Number of subjects: 75
Study 32122951 — intervention group
Group type: EXPERIMENTAL
Intervention: Humorous digital media attention diversion (watching humorous movies)
Number of subjects: 66
Study 32122951 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-humorous digital media attention diversion (watching non-humorous movies)
Number of subjects: 66
Study 32122951 — intervention group
Group type: EXPERIMENTAL
Intervention: Humorous digital media attention diversion
Number of subjects: 66
Study 32122951 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-humorous digital media attention diversion
Number of subjects: 66
Study 36114824 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemp seed
Number of subjects: 48
Study 36114824 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemp seed + PA
Number of subjects: 48
Study 36114824 — intervention group
Group type: EXPERIMENTAL
Intervention: PA
Number of subjects: 48
Study 36114824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 33963984 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention targeting self-efficacy
Number of subjects: 270
Study 32376080 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy (PST)
Number of subjects: 32
Study 32376080 — intervention group
Group type: EXPERIMENTAL
Intervention: Engage therapy
Number of subjects: 32
Study 36044093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose
Number of subjects: 11
Study 34081034 — intervention group
Group type: EXPERIMENTAL
Intervention: Paratracheal pressure
Number of subjects: 140
Study 34081034 — intervention group
Group type: COMPARATOR
Intervention: Cricoid pressure
Number of subjects: 140
Study 36102618 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume recruitment (LVR) used twice-daily
Number of subjects: 11
Study 36102618 — intervention group
Group type: EXPERIMENTAL
Intervention: LVR
Number of subjects: 11
Study 34343033 — intervention group
Group type: EXPERIMENTAL
Intervention: Avapritinib 300 mg once daily (4 weeks continuously)
Number of subjects: 476
Study 34343033 — intervention group
Group type: COMPARATOR
Intervention: Regorafenib 160 mg once daily (3 weeks on and 1 week off)
Number of subjects: 476
Study 34343033 — intervention group
Group type: EXPERIMENTAL
Intervention: Avapritinib
Number of subjects: 476
Study 34343033 — intervention group
Group type: COMPARATOR
Intervention: Regorafenib
Number of subjects: 476
Study 32600363 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (9-day course)
Number of subjects: 24
Study 32600363 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pantoprazole)
Number of subjects: 24
Study 36273187 — intervention group
Group type: EXPERIMENTAL
Intervention: online CBT modules with asynchronous therapist feedback
Number of subjects: 1000
Study 36273187 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 1000
Study 32699049 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 400
Study 32699049 — intervention group
Group type: COMPARATOR
Intervention: Conventional phacoemulsification surgery (CPS)
Number of subjects: 400
Study 32699049 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrastromal femtosecond laser-assisted astigmatic keratotomies (iFAKs)
Number of subjects: 400
Study 32699049 — intervention group
Group type: COMPARATOR
Intervention: Manual limbal relaxing incisions (LRIs)
Number of subjects: 400
Study 34916330 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated intervention (INT)
Number of subjects: 631
Study 34916330 — intervention group
Group type: COMPARATOR
Intervention: Improved mental healthcare (MHC)
Number of subjects: 631
Study 34916330 — intervention group
Group type: COMPARATOR
Intervention: Service as usual (SAU)
Number of subjects: 631
Study 34916330 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated intervention (INT) and Improved mental healthcare (MHC)
Number of subjects: 631
Study 32873354 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA products
Number of subjects: 17
Study 32873354 — intervention group
Group type: COMPARATOR
Intervention: SFA products (control)
Number of subjects: 17
Study 33103950 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidemia in PALS
Number of subjects: 650
Study 33103950 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercholesterolemia
Number of subjects: 650
Study 33103950 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed dyslipidemia
Number of subjects: 650
Study 33103950 — intervention group
Group type: EXPERIMENTAL
Intervention: Triacylglycerols (TAG) and LDL/HDL
Number of subjects: 650
Study 33103950 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL/HDL and total cholesterol (TCh)
Number of subjects: 650
Study 33103950 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol (TCh)
Number of subjects: 650
Study 33103950 — intervention group
Group type: EXPERIMENTAL
Intervention: TAG
Number of subjects: 650
Study 33103950 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid parameters
Number of subjects: 650
Study 33103950 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic ALS and PMA
Number of subjects: 650
Study 33103950 — intervention group
Group type: EXPERIMENTAL
Intervention: PBP
Number of subjects: 650
Study 35166190 — intervention group
Group type: EXPERIMENTAL
Intervention: ICCMS
Number of subjects: 240
Study 35166190 — intervention group
Group type: COMPARATOR
Intervention: CCMS
Number of subjects: 240
Study 34496899 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (MPH), administered twice daily, dosage based on age and body weight.
Number of subjects: 6
Study 34496899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 37823711 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% caloric restriction (CR) for 2 years
Number of subjects: 90